US7560107B2
(en)
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
AU2002248329B2
(en)
*
|
2001-01-12 |
2007-06-28 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
WO2003031598A2
(en)
|
2001-10-05 |
2003-04-17 |
Emory University |
Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
|
EP1456235A4
(en)
*
|
2001-11-30 |
2005-08-17 |
Univ Emory |
VARIANTS OF DOMAIN C2 OF FACTOR VIII
|
GB0207092D0
(en)
*
|
2002-03-26 |
2002-05-08 |
Sod Conseils Rech Applic |
Stable pharmaceutical composition containing factor VIII
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
JP4644663B2
(ja)
*
|
2003-06-03 |
2011-03-02 |
セル ジェネシス インコーポレイテッド |
ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
DE602004007924T2
(de)
*
|
2003-06-26 |
2008-04-10 |
Merck Patent Gmbh |
Thrombopoietinproteine mit verbesserten eigenschaften
|
US20050059023A1
(en)
*
|
2003-09-16 |
2005-03-17 |
Cantor Thomas L. |
Methods and kits for monitoring resistance to therapeutic agents
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
EP1699469B1
(en)
*
|
2003-12-03 |
2010-04-07 |
University of Rochester |
Recombinant factor viii having increased specific activity
|
EP1750733B1
(en)
*
|
2004-05-03 |
2013-12-11 |
Emory University |
METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
|
WO2005123928A1
(en)
*
|
2004-06-08 |
2005-12-29 |
Battelle Memorial Institute |
Production of human coagulation factor viii from plant cells and whole plants
|
DK2363414T3
(da)
*
|
2004-11-12 |
2022-08-08 |
Bayer Healthcare Llc |
Stedstyret modifikation af FVIII
|
US20100256062A1
(en)
|
2004-12-06 |
2010-10-07 |
Howard Tommy E |
Allelic Variants of Human Factor VIII
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
JP2009518345A
(ja)
|
2005-12-07 |
2009-05-07 |
テフニーシェ ウニヴェルジテート ミュンヘン |
因子viiiおよび因子viii様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
AU2007236280B2
(en)
*
|
2006-04-11 |
2013-07-25 |
Csl Behring Gmbh |
Method of increasing the in vivo recovery of therapeutic polypeptides
|
US7939632B2
(en)
*
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
EP1935430A1
(en)
*
|
2006-12-22 |
2008-06-25 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
JP5448839B2
(ja)
*
|
2006-12-22 |
2014-03-19 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
インビボで長い半減期を有する修飾された凝固因子
|
FR2913020B1
(fr)
*
|
2007-02-23 |
2012-11-23 |
Biomethodes |
Nouveaux facteurs viii pour le traitement des hemophiles de type a
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
RU2531493C2
(ru)
|
2007-11-01 |
2014-10-20 |
Юниверсити Оф Рочестер |
Рекомбинантный фактор viii, обладающий повышенной стабильностью
|
EP2149603A1
(en)
|
2008-07-28 |
2010-02-03 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
|
KR101544245B1
(ko)
|
2009-02-03 |
2015-08-12 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
|
LT2440239T
(lt)
|
2009-06-09 |
2017-12-11 |
Prolong Pharmaceuticals, LLC |
Hemoglobino kompozicijos
|
EP3222287A1
(en)
|
2009-08-24 |
2017-09-27 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
EP2498804A4
(en)
*
|
2009-11-13 |
2013-05-08 |
Puget Sound Blood Ct |
FACTOR VIII IMMUNOGENICITY T LYMPHOCYTE T EPOXY VARIANTS
|
JP5903048B2
(ja)
|
2009-12-06 |
2016-04-13 |
バイオジェン ヘモフィリア インコーポレイテッド |
第VIII−Fc因子キメラおよびハイブリッドポリペプチドならびにその使用法
|
US20110177107A1
(en)
*
|
2010-01-14 |
2011-07-21 |
Haplomics, Inc. |
Predicting and reducing alloimmunogenicity of protein therapeutics
|
DK2591006T3
(da)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
DK2635297T3
(da)
|
2010-11-05 |
2019-05-06 |
Baxalta GmbH |
En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
|
WO2012094532A1
(en)
*
|
2011-01-05 |
2012-07-12 |
Expression Therapeutics, Llc |
Method and system for suspension cell culture
|
EP3527218A1
(en)
|
2011-06-10 |
2019-08-21 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
EP4169525A1
(en)
|
2011-07-08 |
2023-04-26 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
CN102277379B
(zh)
*
|
2011-08-18 |
2013-07-24 |
中国科学院遗传与发育生物学研究所 |
表达凝血因子viii的表达载体及其应用
|
BR112014017165B1
(pt)
|
2012-01-12 |
2023-05-02 |
Bioverativ Therapeutics Inc |
Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
|
DK2802668T3
(en)
|
2012-01-12 |
2018-11-19 |
Bioverativ Therapeutics Inc |
METHODS FOR REDUCING IMMUNOGENICITY AGAINST FACT VIII OF INDIVIDUALS THAT UNDERSTAND FACT VIII THERAPY
|
SI2814840T1
(sl)
|
2012-02-15 |
2020-06-30 |
Bioverativ Therapeutics Inc. |
Sestavki faktorja VIII in postopki njihove izdelave in uporabe
|
EA201491388A1
(ru)
|
2012-02-15 |
2015-01-30 |
Байоджен Айдек Ма Инк. |
Рекомбинантные белки фактора viii
|
EP2666782A1
(en)
*
|
2012-05-22 |
2013-11-27 |
Imnate Sarl |
Coagulation factor VIII with reduced immunogenicity.
|
CA2875246A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
US10202595B2
(en)
|
2012-06-08 |
2019-02-12 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
DK2882450T3
(da)
|
2012-07-11 |
2020-02-24 |
Bioverativ Therapeutics Inc |
Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
|
EP2877202A4
(en)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
BLOOD FACTOR MONITORING TEST AND USES THEREOF
|
US10391152B2
(en)
|
2012-10-18 |
2019-08-27 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
EP2928303A4
(en)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
|
PT2956477T
(pt)
|
2013-02-15 |
2021-02-05 |
Bioverativ Therapeutics Inc |
Gene do fator viii otimizado
|
LT2968477T
(lt)
|
2013-03-15 |
2020-03-10 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii polipeptido kompozicijos
|
AR095527A1
(es)
|
2013-03-15 |
2015-10-21 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix
|
SG10201913738YA
(en)
|
2013-06-28 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Thrombin cleavable linker with xten and its uses thereof
|
US10947269B2
(en)
|
2013-08-08 |
2021-03-16 |
Bioverativ Therapeutics Inc. |
Purification of chimeric FVIII molecules
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
CN105848670A
(zh)
|
2013-10-22 |
2016-08-10 |
Dbv技术公司 |
通过诱导对血液因子的耐受治疗血友病的方法
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
WO2015085276A1
(en)
|
2013-12-06 |
2015-06-11 |
Biogen Idec Ma Inc. |
Population pharmacokinetics tools and uses thereof
|
EP2881463A1
(en)
|
2013-12-09 |
2015-06-10 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
|
PT4176894T
(pt)
|
2014-01-10 |
2024-05-21 |
Bioverativ Therapeutics Inc |
Proteínas quiméricas de fator viii e utilizações destas
|
JP6609561B2
(ja)
|
2014-02-04 |
2019-11-20 |
バイオジェン・エムエイ・インコーポレイテッド |
翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
|
CA2940127A1
(en)
*
|
2014-02-19 |
2015-08-27 |
Bloodworks |
Factor viii b cell epitope variants having reduced immunogenicity
|
WO2015132724A1
(en)
|
2014-03-05 |
2015-09-11 |
Pfizer Inc. |
Improved muteins of clotting factor viii
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
AU2016354550B2
(en)
|
2015-11-13 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
US10189888B2
(en)
|
2015-11-13 |
2019-01-29 |
Baxalta Incorporated |
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
|
US11753461B2
(en)
|
2016-02-01 |
2023-09-12 |
Bioverativ Therapeutics Inc. |
Optimized factor VIII genes
|
EP3476937A4
(en)
|
2016-06-24 |
2019-12-04 |
Mogam Institute for Biomedical Research |
CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
CA3063204A1
(en)
*
|
2017-05-09 |
2018-11-15 |
Emory University |
Clotting factor variants and their use
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
CA3090136A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
BR112020020084A2
(pt)
|
2018-04-04 |
2021-01-05 |
Sigilon Therapeutics, Inc. |
Partícula, preparação de uma pluralidade de partículas, método de preparação de uma partícula, e, composição de partículas.
|
MX2020012397A
(es)
|
2018-05-18 |
2021-04-12 |
Bioverativ Therapeutics Inc |
Metodos de tratamiento de la hemofilia a.
|
KR20210034013A
(ko)
|
2018-07-16 |
2021-03-29 |
박스알타 인코퍼레이티드 |
발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
|
US20200069817A1
(en)
|
2018-08-09 |
2020-03-05 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
TW202039546A
(zh)
|
2019-01-16 |
2020-11-01 |
美商巴克斯歐塔公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
JP2022537200A
(ja)
|
2019-06-19 |
2022-08-24 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病および低骨ミネラル密度を処置するための方法および組成物
|
CN114375205A
(zh)
|
2019-06-20 |
2022-04-19 |
武田药品工业株式会社 |
用基于病毒的基因疗法进行治疗的方法
|
JP2023506171A
(ja)
|
2019-12-12 |
2023-02-15 |
武田薬品工業株式会社 |
発現が上昇した組換えfviiiバリアントをコードするウイルスベクターを使用する、血友病aの遺伝子療法
|
TW202246505A
(zh)
*
|
2021-03-05 |
2022-12-01 |
俄羅斯聯邦商亞那拜恩有限公司 |
編碼凝血因子ix蛋白的密碼子優化的核酸及其用途
|
JP2024514307A
(ja)
|
2021-03-31 |
2024-04-01 |
ヘモネティクス・コーポレーション |
血液凝固測定装置の品質管理配合物
|
WO2022264040A1
(en)
|
2021-06-14 |
2022-12-22 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
AR126846A1
(es)
|
2021-08-23 |
2023-11-22 |
Bioverativ Therapeutics Inc |
Genes del factor viii optimizados
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|